Skip to main content

18 Result(s)

within Elihu H. Estey Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

    Jacob S. Appelbaum, Andrew H. Wei, Sumithra J. Mandrekar, Ing S. Tiong… in Leukemia (2024)

  2. Article

    Open Access

    Time independent factors that predict relapse in adults with acute myeloid leukemia

    John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell… in Blood Cancer Journal (2024)

    Download PDF (438 KB) View Article

  3. Article

    Open Access

    Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

    Secondary AML (sAML), defined by either history of antecedent hematologic disease (AHD) or prior genotoxic therapy (tAML), is classically regarded as having worse prognosis than de novo disease (dnAML). Clinic...

    Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alex Ambinder… in Leukemia (2023)

    Download PDF (512 KB) View Article

  4. Article

    Open Access

    Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms

    Gabrielle Paras, Megan Othus, Kelda Schonhoff, Carole Shaw, Mohamed Sorror… in Leukemia (2023)

    Download PDF (529 KB) View Article

  5. No Access

    Article

    Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients

    Nicole Mostofi, Carole Shaw, Roland B. Walter, Mary-Elizabeth M. Percival… in Leukemia (2022)

  6. No Access

    Article

    Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm

    Anna B. Halpern, Megan Othus, Genevieve Alcorn, Zahra Ali… in Leukemia (2022)

  7. No Access

    Article

    Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies

    Noam E. Kopmar, Megan Othus, Kelda M. Gardner, Carole Shaw, Anna B. Halpern… in Leukemia (2022)

  8. No Access

    Article

    Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

    Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey in Leukemia (2021)

  9. Article

    Open Access

    Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

    Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and child...

    Jorge E. Cortes, Marcos de Lima, Hervé Dombret… in Journal of Hematology & Oncology (2020)

    Download PDF (828 KB) View Article

  10. No Access

    Article

    Need for routine examination of left ventricular ejection fraction in patients with AML

    Hiba M. Khan, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Emily M. Huebner… in Leukemia (2020)

  11. No Access

    Article

    Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

    Anna B. Halpern, Nicholas P. Howard, Megan Othus, Paul C. Hendrie… in Leukemia (2020)

  12. No Access

    Article

    Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials

    Megan Othus, Elihu H. Estey, Guillermo Garcia-Manero, Brent L. Wood… in Leukemia (2019)

  13. No Access

    Article

    Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

    Outcomes with “7 + 3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompt...

    Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker… in Leukemia (2018)

  14. Article

    New drugs in AML: uses and abuses

    Elihu H. Estey, Robert Peter Gale, Mikkael A. Sekeres in Leukemia (2018)

    Download PDF (243 KB) View Article

  15. No Access

    Article

    Acute Myeloid Leukemia with Normal Cytogenetics

    Acute myeloid leukemia (AML) is proving to be a heterogeneous disease process that is driven by various genetic mutations and aberrant protein expression. As our population ages, the incidence of AML is likely...

    Raya Mawad, Elihu H. Estey in Current Oncology Reports (2012)

  16. No Access

    Book

    Leukemia and Related Disorders

    Integrated Treatment Approaches

    Elihu H. Estey, Fred R. Appelbaum in Contemporary Hematology (2012)

  17. No Access

    Article

    A New Statistical Method for Dose-Finding Based on Efficacy and Toxicity in Early Phase Clinical Trials

    Most statistical methods for dose-finding in phase I clinical trials determine a maximum tolerable dose based on toxicity while ignoring efficacy. Most phase II designs assume that an acceptable dose has been ...

    Peter F. Thall, Elihu H. Estey, Hsi-Guang Sung in Investigational New Drugs (1999)

  18. No Access

    Chapter

    Prognosis and therapy of myelodysplastic syndromes

    This chapter will deal primarily with issues faced by physicians in the management of patients with myelodysplastic syndromes (MDSs). Accordingly, emphasis will be placed on assessing these patients’ prognoses...

    Elihu H. Estey in Leukemia: Advances in Research and Treatment (1993)